There is considerable data showing that disparities in payment across sites of service increase costs to patients, insurers and taxpayers as well as result in marketplace consolidation that limits patient choice by reducing access to care in the community-setting.

May 29, 2013

Results of Analyses for Chemotherapy Administration Utilization and Chemotherapy Drug Utilization, 2005-2011 for Medicare Fee- for-Service Beneficiaries, The Moran Company, May 29, 2013

The Moran Company was asked by The US Oncology Network, Community Oncology Alliance, and ION Solutions to conduct a series of analyses regarding the hypothesis that there has been a shift in the site of service for chemotherapy services in Medicare from the physician office to the Hospital Outpatient Department (HOPD).  This memo provides detailed […]

Research
March 17, 2012

Total Cost of Cancer Care by Site of Service: Physician Office vs Outpatient Hospital, Avalere Health, LLC, March 2012

Avalere Health analyzed three years of commercial health plan data to examine the differences in the total cost of care for cancer patients based on the site of service of chemotherapy or radiation therapy. Our study compared the average total episode costs for patients receiving treatment for cancer in a physician’s office (including freestanding radiation […]

Research
October 19, 2011

Site of Service Cost Differences for Medicare Patients Receiving Chemotherapy, Milliman, October 19, 2011

National spending on cancer care in 2010 is estimated at $125 billion. About 8 million of the almost 14 million Americans living with cancer are over age 65, and approximately half of cancer care spending is associated with Medicare beneficiaries.  Approximately 12% of active cancer patients among Medicare beneficiaries receive chemotherapy in a given year, […]

Research